Are Cannabinoids Better Than Existing MS Treatments for Pain and Spasticity? | Research

The takeaway

A review found that while cannabinoids can reduce spasticity and pain, there were too few controlled trials to conclude they were superior to conventional MS medications, and smoking cannabis carried additional respiratory risks.

Read this if you have MS and want a balanced view of how cannabinoids compare to conventional medications.

Too few trials to conclude cannabinoids are superior to conventional MS drugs

What the researchers found

The review acknowledged substantial evidence that cannabinoids could reduce muscle spasticity and pain through CB1 receptor mechanisms. However, in the specific context of multiple sclerosis, the evidence for superiority over existing treatments was questionable. For spasticity, too few controlled trials existed to draw reliable conclusions. For pain, most available trials suggested cannabinoids were not superior to existing treatments, though few had examined chronic pain syndromes relevant to MS.

The author argued that synthetic cannabinoids targeting specific receptor subtypes would likely prove more therapeutically useful than THC itself, which activates both CB1 and CB2 receptors broadly. Non-smoked delivery methods (such as aerosol) were recommended to avoid respiratory risks.

Why it matters

This review provided a more cautious assessment than many contemporaneous reviews, emphasizing that demonstrating an effect is not the same as demonstrating superiority over existing treatments. The argument for synthetic, receptor-selective cannabinoids over whole-plant cannabis represented a pharmacological perspective that would influence drug development efforts.

The numbers in context

No specific quantitative data were highlighted in the abstract.

How the study worked

This was a narrative review evaluating clinical trial evidence, preclinical data, and pharmacological considerations for cannabinoid use in MS-related pain and spasticity.

What this study cannot tell us

As a narrative review, the assessment reflected the author's interpretation of limited evidence. The review did not use systematic review methodology. The evidence base at the time was dominated by small trials.

How to read the evidence

This is a narrative review synthesizing limited clinical evidence, providing moderate-level evidence through expert analysis.

When this study was published

Published in 2002, before the CAMS trial results and Sativex approval.

The bigger picture

Subsequent large trials and the approval of Sativex partially addressed the evidence gaps identified here. The prediction that synthetic, selective cannabinoids would prove superior has not been fully realized; Sativex, a plant-derived product, rather than a synthetic selective agonist, became the approved medication.

Questions still open

Have subsequent larger trials demonstrated cannabinoid superiority over conventional MS treatments? Why has the development of receptor-selective synthetic cannabinoids for MS not progressed as anticipated?

Common questions

Should MS patients use cannabis instead of their current medications?

This review cautioned that there was insufficient evidence to conclude cannabinoids were better than existing MS treatments. It recommended synthetic cannabinoids over smoked cannabis and suggested non-smoked delivery methods.

Why did the author recommend synthetic cannabinoids over natural cannabis?

The author argued that synthetic compounds targeting specific cannabinoid receptors could provide therapeutic benefits without the broad effects and psychoactivity of THC, and without the respiratory risks of smoking.

Read the original research

Cannabinoids in the treatment of pain and spasticity in multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000), 3(6), 859-64

View on PubMed ↗

Citation

Smith, Paul F. (2002). Cannabinoids in the treatment of pain and spasticity in multiple sclerosis.. Current opinion in investigational drugs (London, England : 2000), 3(6), 859-64.